Determination of Lipoxygenase, CYP450, and Non-Enzymatic Metabolites of Arachidonic Acid in Essential Hypertension and Type 2 Diabetes.

arachidonic acid dihydroxyeicosatrienoic acids epoxyeicosatrienoic acids hydroxyeicosatrienoic acids hyperglycemic clamp hyperinsulinemic clamp hypertension oxylipins type 2 diabetes

Journal

Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790

Informations de publication

Date de publication:
13 Sep 2022
Historique:
received: 03 08 2022
revised: 30 08 2022
accepted: 12 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

Type 2 diabetes (T2D) and hypertension (HTN) are common risk factors of cardiovascular diseases (CVD) characterized by chronic low-grade systemic inflammation and impaired endothelial function. This study aimed to assess whether levels of non-enzymatic, lipoxygenase (LOX)- and cytochrome P450 (CYP)-derived arachidonic acid (ARA) metabolites, which are known regulators of vascular homeostasis, are affected by HTN and T2D. For this objective, 17 plasma level derivatives of ARA were quantitated by chromatography coupled with mass spectrometry in 44 patients (12 healthy, 8 HTN, 7 T2D, and 17 HTN + T2D). Effects of hyperglycemic and hyperinsulinemic clamps on ARA metabolite levels were assessed in seven healthy subjects. No significant differences in the plasma levels of ARA metabolites were observed for T2D patients compared with healthy volunteers. HTN was associated with an alteration of ARA metabolite correlation patterns with increased 20-, 19-, 15-, and 8-hydroxyeicosatrienoic acid (HETE). A decrease of 20-HETE was also observed during both hyperglycemic and hyperinsulinemic clamps. Additional experiments are needed to assess whether the modulation of HETE metabolites in HTN may be of interest. Furthermore, although not affected by T2D, it remains to investigate whether the decrease of 20-HETE observed during clamps may be related to the regulation of glucose tolerance and insulin signaling.

Identifiants

pubmed: 36144261
pii: metabo12090859
doi: 10.3390/metabo12090859
pmc: PMC9501142
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fondation de France
ID : 2011-20459
Organisme : Agence Nationale de la Recherche
ID : ANR-16-CE17-0012

Références

Science. 2021 Jul 2;373(6550):
pubmed: 34210852
Biochim Biophys Acta. 2013 Dec;1832(12):2216-31
pubmed: 23994612
Adv Nutr. 2015 Sep 15;6(5):513-40
pubmed: 26374175
Eur Cardiol. 2019 Apr;14(1):50-59
pubmed: 31131037
J Cardiovasc Pharmacol. 2010 Oct;56(4):336-44
pubmed: 20930591
J Adv Res. 2018 Mar 13;11:23-32
pubmed: 30034873
Microvasc Res. 2018 Sep;119:7-12
pubmed: 29596860
J Mol Cell Cardiol. 2018 Apr;117:88-99
pubmed: 29428638
BMJ Open Diabetes Res Care. 2022 Mar;10(2):
pubmed: 35361620
Anal Chem. 2003 Jul 1;75(13):3019-30
pubmed: 12964746
Prostaglandins Leukot Essent Fatty Acids. 2008 Dec;79(6):215-22
pubmed: 19042114
Thromb Res. 2016 Aug;144:192-201
pubmed: 27393924
Free Radic Biol Med. 2013 Jun;59:45-55
pubmed: 22940496
Antioxid Redox Signal. 2015 May 10;22(14):1273-92
pubmed: 25330284
Cell Biol Toxicol. 2015 Oct;31(4-5):241-59
pubmed: 26493311
Endocrine. 2016 Nov;54(2):371-382
pubmed: 27568038
J Adv Res. 2018 Jan 04;11:43-55
pubmed: 30034875
Hypertension. 2014 Dec;64(6):1299-305
pubmed: 25225211
J Hypertens. 2006 Nov;24(11):2231-8
pubmed: 17053545
Signal Transduct Target Ther. 2021 Feb 26;6(1):94
pubmed: 33637672
Bioorg Med Chem Lett. 2019 Oct 1;29(19):126616
pubmed: 31439380
Drug Metab Dispos. 2018 Aug;46(8):1157-1168
pubmed: 29880629
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1768-74
pubmed: 12947015
J Pharmacol Exp Ther. 1991 Jan;256(1):194-203
pubmed: 1824864
Hypertension. 2004 Feb;43(2):388-92
pubmed: 14707157
Int J Mol Sci. 2018 Oct 23;19(11):
pubmed: 30360467
Physiol Rev. 2002 Jan;82(1):131-85
pubmed: 11773611
Circ Res. 2017 May 26;120(11):1776-1788
pubmed: 28325781
Cardiovasc Diabetol. 2019 Mar 18;18(1):35
pubmed: 30885203
Circ Res. 1996 Mar;78(3):415-23
pubmed: 8593700
Bioanalysis. 2012 Oct;4(19):2343-56
pubmed: 23088461
J Am Heart Assoc. 2020 Oct 20;9(19):e017598
pubmed: 32975162
Anal Bioanal Chem. 2018 Sep;410(23):6009-6029
pubmed: 30074088
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Dec;1863(12):1511-1522
pubmed: 30308322
Molecules. 2019 Apr 25;24(8):
pubmed: 31027298
Biochim Biophys Acta. 2015 Apr;1851(4):340-55
pubmed: 25449650
J Pharmacol Exp Ther. 1995 Jun;273(3):1182-9
pubmed: 7791089
Prostaglandins Other Lipid Mediat. 2021 Feb;152:106485
pubmed: 33011364
Nat Commun. 2018 Jan 12;9(1):177
pubmed: 29330456
Int J Mol Sci. 2019 Jul 27;20(15):
pubmed: 31357612
Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H495-507
pubmed: 19525377
J Lipid Res. 2020 Nov;61(11):1424-1436
pubmed: 32848050
Cardiovasc Endocrinol. 2017 Feb 15;6(1):33-38
pubmed: 31646117

Auteurs

Guillaume Feugray (G)

CHU Rouen, Department of General Biochemistry, Normandie University, F-76000 Rouen, France.
UNIROUEN, INSERM U1096, Normandie University, F-76000 Rouen, France.

Tony Pereira (T)

CHU Rouen, Department of Pharmacology, F-76000 Rouen, France.

Michèle Iacob (M)

CHU Rouen, Department of Pharmacology, F-76000 Rouen, France.

Lucile Moreau-Grangé (L)

CHU Rouen, Department of Endocrinology, Diabetes and Metabolic Diseases, Normandie University, F-76000 Rouen, France.
CHU Rouen, CIC-CRB U1404, F-76000 Rouen, France.

Gaëtan Prévost (G)

CHU Rouen, Department of Endocrinology, Diabetes and Metabolic Diseases, Normandie University, F-76000 Rouen, France.
CHU Rouen, CIC-CRB U1404, F-76000 Rouen, France.
UNIROUEN, INSERM U1239, Normandie University, F-76000 Rouen, France.

Valéry Brunel (V)

CHU Rouen, Department of General Biochemistry, Normandie University, F-76000 Rouen, France.

Robinson Joannidès (R)

UNIROUEN, INSERM U1096, Normandie University, F-76000 Rouen, France.
CHU Rouen, Department of Pharmacology, F-76000 Rouen, France.
CHU Rouen, CIC-CRB U1404, F-76000 Rouen, France.

Jérémy Bellien (J)

UNIROUEN, INSERM U1096, Normandie University, F-76000 Rouen, France.
CHU Rouen, Department of Pharmacology, F-76000 Rouen, France.
CHU Rouen, CIC-CRB U1404, F-76000 Rouen, France.

Thomas Duflot (T)

UNIROUEN, INSERM U1096, Normandie University, F-76000 Rouen, France.
CHU Rouen, Department of Pharmacology, F-76000 Rouen, France.
CHU Rouen, CIC-CRB U1404, F-76000 Rouen, France.

Classifications MeSH